In the panorama of scientific research dedicated to human health, every progress, however small, represents a significant step towards a better quality of life and a more sustainable future. A recent discovery, the result of the synergy between public research and the Italian pharmaceutical industry, lights up new hopes in the fight against breast cancer, a disease that affects millions of women around the world.
A step forward in the fight against breast cancer
A team of researchers from the Institute of endotypes in oncology, metabolism and immunology of the National Research Council (Cnr-Ieomi) of Naples, in collaboration with the pharmaceutical company Dompé farmaceutici SpA, has revealed a previously unknown molecular mechanism that could revolutionize the therapeutic approach. The study, published in the prestigious journal Cell Death & Diseaseidentified a protein, called Shp1, that can slow the progression of breast cancer.
Shp1, the molecular switch that slows down tumor aggressiveness
At the center of this discovery is the interaction between Shp1 and interleukin 8 (IL-8), a protein known to be involved in the aggressiveness of tumors. IL-8 is like an accelerator for cancer cells: produced in the environment surrounding the tumor, it promotes its uncontrolled growth and ability to invade healthy tissues, paving the way for the formation of metastases. The novelty is that Shp1, already known for its anti-tumor properties, acts as a real molecular “switch”, blocking the signaling chain started by IL-8 and, in fact, “turning off” its pro-tumor action.
But the complexity of the mechanism does not stop there. The researchers discovered a fascinating self-regulatory dynamic: IL-8 is also able to influence Shp1. Through a chemical modification, IL-8 can deactivate Shp1, triggering a series of events that lead to the destruction of the receptor through which the signal is transmitted. This means that the tumor has a sort of intrinsic mechanism to regulate its aggressiveness, an aspect that was completely unknown until now.
The impact on the most aggressive tumors and therapeutic prospects
«We have identified a completely new way in which tumor cells regulate the IL-8 signal, controlling the stability of its receptor», explains Alessia Varone, Cnr-Ieomi researcher and coordinator of the study. “This mechanism had never been described before and paves the way for the study of similar processes for other crucial proteins in the tumor environment.”
The relevance of this finding is amplified by the fact that the Shp1/IL-8 mechanism is particularly active in two of the most difficult to treat breast cancer subtypes: luminal tumors and, especially, so-called triple-negative tumors. In the latter case, low levels of Shp1 were associated with high IL-8 production and a poorer prognosis. This suggests that the identified molecular pathway could not only act as a prognostic marker to evaluate the severity of the disease, but also become a target for new targeted therapies, capable of acting in a more specific and potentially more effective way.
The synergy between public research and industry: a successful model
A key element that contributed to the success of this study is the close integration between basic research, conducted by a public institution such as the Cnr, and the pharmaceutical industry, represented by Dompé farmaceutici SpA. This collaboration made it possible to accelerate the path from laboratory discovery to the evaluation of possible clinical applications, shortening the time between pure research and its translation into concrete benefits for patients.
«Our data suggest that acting on this mechanism could represent an innovative strategy to combat the most aggressive tumors», adds Daniela Corda, researcher at the Cnr-Ieomi and senior co-author of the work. «It is a concrete example of how collaboration between public research and the pharmaceutical industry can accelerate the transfer of knowledge towards clinical applications».
Future prospects: a wider ray of hope
The importance of interleukin 8 is not limited to breast cancer. This protein also plays an important role in other solid tumors, such as those of the lung, pancreas and prostate. This means that the discovery of a molecular switch like Shp1, capable of regulating its activity, could have potentially broader applications, offering new therapeutic strategies for a much broader oncological context.
This research is not only a victory for Italian science, but a true beacon of hope for thousands of patients. It demonstrates how ongoing commitment to research, combined with strategic collaborations, can lead to innovations that improve human health and help build a healthier and ultimately more sustainable future for all.
